Estrogen receptor (ER)-negative breast cancer is an aggressive form that currently requires
more drug treatment options. Thus, we have further modified cyclohexanone derivatives of …

There is a need for the development of new, safe and efficacious drug therapies for the
treatment of estrogen receptor (ER)-negative breast cancers. RL71 is a second-generation …

Novel bis (hydroxymethyl) alkanoate curcuminoid derivatives were designed, synthesized
and screened for in vitro antiproliferative and in vivo antitumor activity. Selected new …

A series of 18 heterocyclic cyclohexanone analogues of curcumin have been synthesised
and screened for their activity in both adherent and non-adherent cancer cell models …

There is a need for the development of new safe and efficacious drug therapies for the
treatment of estrogen receptor (ER)‑negative breast cancers. 1-Methyl-3, 5-bis [(E)-4-pyridyl) …

We analyzed antitumor effects of a series of curcumin analogues. Some of them were
obtained by reaction of substitution involving the two phenolic OH groups of curcumin while …

MATERIALS AND METHODS: We compared the impact of bis-1, 7-2 (hydroxyphenil)-hepta-
1, 6diene-3, 5diore (BDMC-A) with that of curcumin in human breast cancer cell line MCF-7 …

In our study, we present experimental evidence suggesting that curcumin exerts multiple
different suppressive effects on human breast carcinoma cells in vitro. Our experiments …

Curcumin is a potential plant‐derived drug for the treatment of breast cancer. Poor solubility
and bioavailability are the main factors that limit its clinical application. Various structural …

Curcumin has a variety of anticancer properties, but low bioavailability prevents its use in
chemotherapeutic applications. To address this problem, we tested the efficacy of the …